The biopharma company Amarin is making some heart-medicine history Monday with its proprietary, prescription formulation of fish oil, called Vascepa.
In a stunning clinical trial result that upends years of skepticism about the long-term heart benefit of products containing omega-3 fatty acids, Amarin’s Vascepa significantly reduced the risk of deaths, heart attacks, strokes, and other serious cardiovascular events compared to a placebo.
I don’t know all the “inactive” ingredients in this product, but many OTC fish oil products have Vitamin E added, ostensibly as a preservative. Some patients might benefit just from that.
Comments are closed.